{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:42:22Z","timestamp":1792806142479,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04406-5","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:48:18Z","timestamp":1780577298000},"page":"5221-5230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-positive advanced or metastatic gastric or gastroesophageal cancer: a meta-analysis of single-arm trials"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6795-7189","authenticated-orcid":false,"given":"Akhil Deepak","family":"Vatvani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyad","family":"Al Jabiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehad","family":"Shabarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"3","key":"4406_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4406_CR2","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cgh.2019.07.045","volume":"18","author":"AP Thrift","year":"2020","unstructured":"Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol. 2020;18(3):534\u201342. https:\/\/doi.org\/10.1016\/j.cgh.2019.07.045.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4406_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1327055","volume":"14","author":"H Li","year":"2024","unstructured":"Li H, Shen M, Wang S. Current therapies and progress in the treatment of advanced gastric cancer. Front Oncol. 2024;14:1327055. https:\/\/doi.org\/10.3389\/fonc.2024.1327055.","journal-title":"Front Oncol"},{"key":"4406_CR4","unstructured":"Menon G, Kumar R. Gastric Cancer [Internet]. 2024. (StatPearls [Internet]). Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459142\/"},{"issue":"4758","key":"4406_CR5","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1126\/science.3012781","volume":"232","author":"T Akiyama","year":"1986","unstructured":"Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c- erb B-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 1986;232(4758):1644\u20136. https:\/\/doi.org\/10.1126\/science.3012781.","journal-title":"Science"},{"key":"4406_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7150\/jca.4090","volume":"3","author":"JT J\u00f8rgensen","year":"2012","unstructured":"J\u00f8rgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer - a systematic analysis of data from the literature. J Cancer. 2012;3:137\u201344. https:\/\/doi.org\/10.7150\/jca.4090.","journal-title":"J Cancer"},{"issue":"6","key":"4406_CR7","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1309\/VACP-VLQA-G9DX-VUDF","volume":"113","author":"MP Hoang","year":"2000","unstructured":"Hoang MP, Sahin AA, Ord\u00f2\u00f1ez NG, Sneige N. HER-2\/neu gene amplification compared with HER-2\/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol. 2000;113(6):852\u20139. https:\/\/doi.org\/10.1309\/VACP-VLQA-G9DX-VUDF.","journal-title":"Am J Clin Pathol"},{"issue":"19","key":"4406_CR8","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i19.4619","volume":"22","author":"LF Abrahao-Machado","year":"2016","unstructured":"Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: an update. World J Gastroenterol. 2016;22(19):4619. https:\/\/doi.org\/10.3748\/wjg.v22.i19.4619.","journal-title":"World J Gastroenterol"},{"issue":"9742","key":"4406_CR9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","journal-title":"Lancet"},{"issue":"12","key":"4406_CR10","doi-asserted-by":"publisher","first-page":"934","DOI":"10.20892\/j.issn.2095-3941.2023.0480","volume":"20","author":"F Wang","year":"2024","unstructured":"Wang F, Ba Y. Treatment strategies for patients with HER2-positive gastric cancer. Cancer Biol Med. 2024;20(12):934\u201341. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2023.0480.","journal-title":"Cancer Biol Med"},{"key":"4406_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2147\/LCTT.S307324","volume":"12","author":"I Azar","year":"2021","unstructured":"Azar I, Alkassis S, Fukui J, Alsawah F, Fedak K, Al Hallak MN, et al. Spotlight on trastuzumab deruxtecan (DS-8201,T-DXd) for her2 mutation positive non-small cell lung cancer. Lung Cancer Targets Ther. 2021;12:103\u201314. https:\/\/doi.org\/10.2147\/LCTT.S307324.","journal-title":"Lung Cancer Targets Ther"},{"issue":"1","key":"4406_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"CA Hudis","year":"2007","unstructured":"Hudis CA. Trastuzumab\u2014mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39\u201351. https:\/\/doi.org\/10.1056\/NEJMra043186.","journal-title":"N Engl J Med"},{"issue":"25","key":"4406_CR13","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2004413.","journal-title":"N Engl J Med"},{"issue":"7","key":"4406_CR14","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"E Van Cutsem","year":"2023","unstructured":"Van Cutsem E, Di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24(7):744\u201356. https:\/\/doi.org\/10.1016\/S1470-2045(23)00215-2.","journal-title":"Lancet Oncol"},{"issue":"9","key":"4406_CR15","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40265-022-01736-w","volume":"82","author":"Z Abuhelwa","year":"2022","unstructured":"Abuhelwa Z, Alloghbi A, Alqahtani A, Nagasaka M. Trastuzumab deruxtecan-induced interstitial lung disease\/pneumonitis in ERBB2-positive advanced solid malignancies: a systematic review. Drugs. 2022;82(9):979\u201387. https:\/\/doi.org\/10.1007\/s40265-022-01736-w.","journal-title":"Drugs"},{"key":"4406_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"issue":"2","key":"4406_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230","volume":"18","author":"NR Haddaway","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020\u202f: an R package and Shiny app for producing PRISMA 2020\u2010compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis. Campbell Syst Rev. 2022;18(2):e1230. https:\/\/doi.org\/10.1002\/cl2.1230.","journal-title":"Campbell Syst Rev"},{"issue":"7","key":"4406_CR18","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1914510.","journal-title":"N Engl J Med"},{"issue":"20","key":"4406_CR19","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA Topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097\u2013108. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2822.","journal-title":"Clin Cancer Res"},{"key":"4406_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211042812","author":"HS Han","year":"2021","unstructured":"Han HS, Kim BJ, Jee HJ, Ryu MH, Park SH, Rha SY, et al. Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16). Ther Adv Med Oncol. 2021. https:\/\/doi.org\/10.1177\/17588359211042812.","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"4406_CR21","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1200\/JCO.2015.62.6598","volume":"34","author":"JR Hecht","year":"2016","unstructured":"Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, et al. Lapatinib in combination with capecitabine plus oxaliplatin in Human Epidermal Growth Factor Receptor 2\u2013positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013\/LOGiC\u2014a randomized phase III trial. J Clin Oncol. 2016;34(5):443\u201351. https:\/\/doi.org\/10.1200\/JCO.2015.62.6598.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4406_CR22","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S1470-2045(17)30111-0","volume":"18","author":"PC Thuss-Patience","year":"2017","unstructured":"Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study. Lancet Oncol. 2017;18(5):640\u201353. https:\/\/doi.org\/10.1016\/S1470-2045(17)30111-0.","journal-title":"Lancet Oncol"},{"key":"4406_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104979","volume":"216","author":"Y Wang","year":"2025","unstructured":"Wang Y, Cheng X, Li X, Chen W, Zhang X, Liu Y. Bystander effect in antibody-drug conjugates: navigating the fine line in tumor heterogeneity. Crit Rev Oncol Hematol. 2025;216:104979. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104979.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"4406_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa2112431","volume":"386","author":"BT Li","year":"2022","unstructured":"Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazi\u00e8res J, et al. Trastuzumab deruxtecan in HER2 -mutant non\u2013small-cell lung cancer. N Engl J Med. 2022;386(3):241\u201351. https:\/\/doi.org\/10.1056\/NEJMoa2112431.","journal-title":"N Engl J Med"},{"issue":"6","key":"4406_CR25","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.21873\/invivo.14143","volume":"39","author":"Y Kanbayashi","year":"2025","unstructured":"Kanbayashi Y, Morioka R, Takayama K, Hosohata K. Disproportionality analysis of gastrointestinal adverse events associated with trastuzumab deruxtecan using the Japanese adverse drug event report database. In Vivo. 2025;39(6):3453\u201360. https:\/\/doi.org\/10.21873\/invivo.14143.","journal-title":"In Vivo"},{"issue":"10","key":"4406_CR26","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.004.","journal-title":"Ann Oncol"},{"issue":"9","key":"4406_CR27","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1136\/gutjnl-2018-318126","volume":"68","author":"M Banks","year":"2019","unstructured":"Banks M, Graham D, Jansen M, Gotoda T, Coda S, Di Pietro M, et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019;68(9):1545\u201375. https:\/\/doi.org\/10.1136\/gutjnl-2018-318126.","journal-title":"Gut"},{"issue":"4","key":"4406_CR28","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1056\/NEJMoa2503119","volume":"393","author":"K Shitara","year":"2025","unstructured":"Shitara K, Van Cutsem E, G\u00fcm\u00fc\u015f M, Lonardi S, De La Fouchardi\u00e8re C, Coutzac C, et al. Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer. N Engl J Med. 2025;393(4):336\u201348. https:\/\/doi.org\/10.1056\/NEJMoa2503119.","journal-title":"N Engl J Med"},{"key":"4406_CR29","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.2147\/DDDT.S508773","volume":"19","author":"D Liao","year":"2025","unstructured":"Liao D, Zhang J, Yan T, Chen Y, Fu Y, Xie N, et al. A systematic review of mechanisms, incidence, and management of trastuzumab deruxtecan induced ILD\/pneumonitis in solid tumors. Drug Des Devel Ther. 2025;19:1655\u201368. https:\/\/doi.org\/10.2147\/DDDT.S508773.","journal-title":"Drug Des Devel Ther"},{"key":"4406_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fgstr.2025.1559934","volume":"4","author":"A Hussain","year":"2025","unstructured":"Hussain A, Iqbal Q, Isaac S, Shariff F, Tariq E, Awais H, et al. Efficacy and safety of trastuzumab deruxtecan in gastrointestinal malignancies: a systemic review and meta-analysis. Front Gastroenterol. 2025;4:1559934. https:\/\/doi.org\/10.3389\/fgstr.2025.1559934.","journal-title":"Front Gastroenterol"},{"issue":"2","key":"4406_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(2):167\u201392. https:\/\/doi.org\/10.6004\/jnccn.2022.0008.","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04406-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04406-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04406-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:01:38Z","timestamp":1792803698000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04406-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["4406"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04406-5","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"23 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest related to this work. The authors acknowledge that this meta-analysis has been presented in the NCCN 2026 Conference.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a systematic review and meta-analysis of previously published studies. As no individual patient-level data were collected and all data were obtained from publicly available sources, ethics approval was not required in accordance with institutional and international guidelines.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was not required in accordance with institutional and international guidelines.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}